Approval · Notice of Compliance 28443 · 2022
AVSOLA: Notice of Compliance 28443
Issued June 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28443
- Date
- June 21, 2022
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional drug substance manufacturing site
- Canadian reference product
- REMICADE
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVSOLA | Not yet assigned | — |
Medicinal ingredients
- INFLIXIMAB 100 MG per VIAL